These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 22444096)

  • 1. B-cell-depleting therapy in systemic lupus erythematosus.
    Ramos-Casals M; Sanz I; Bosch X; Stone JH; Khamashta MA
    Am J Med; 2012 Apr; 125(4):327-36. PubMed ID: 22444096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR; Gordon C
    BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy.
    Bela MM; Espinosa G; Cervera R
    Lupus; 2021 Jan; 30(1):134-140. PubMed ID: 33081591
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of systemic lupus erythematosus with epratuzumab.
    Traczewski P; Rudnicka L
    Br J Clin Pharmacol; 2011 Feb; 71(2):175-82. PubMed ID: 21219397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-cell-targeted therapy for systemic lupus erythematosus: an update.
    Ding C; Foote S; Jones G
    BioDrugs; 2008; 22(4):239-49. PubMed ID: 18611066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab and lupus--a promising pair?
    Ekö SL; van Vollenhoven RF
    Curr Rheumatol Rep; 2014; 16(9):444. PubMed ID: 25074032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.
    Borba HH; Wiens A; de Souza TT; Correr CJ; Pontarolo R
    BioDrugs; 2014 Apr; 28(2):211-28. PubMed ID: 24190520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biological therapies in systemic lupus erythematosus].
    Suszek D; Jeleniewicz R; Majdan M
    Postepy Hig Med Dosw (Online); 2012 Aug; 66():568-73. PubMed ID: 22922157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus.
    Hui-Yuen JS; Nguyen SC; Askanase AD
    Lupus; 2016 Sep; 25(10):1086-96. PubMed ID: 27497253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress.
    Md Yusof MY; Vital EM; Emery P
    Expert Rev Clin Immunol; 2013 Aug; 9(8):761-72. PubMed ID: 23971754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan.
    Muller P; Chowdhury K; Gordon C; Ehrenstein MR; Doré CJ
    Trials; 2020 Jul; 21(1):652. PubMed ID: 32677992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in systemic lupus erythematosus].
    Terrier B; Mouthon L
    Med Sci (Paris); 2013 Jan; 29(1):65-73. PubMed ID: 23351696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-cell targeted treatments for lupus: the journey counts as much as the destination.
    Falgarone G; Dhote R; Boissier MC
    Joint Bone Spine; 2012 Oct; 79(5):437-40. PubMed ID: 22480746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies.
    Fattah Z; Isenberg DA
    Expert Opin Biol Ther; 2014 Mar; 14(3):311-26. PubMed ID: 24387632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
    BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the use of biologics in lupus.
    Relan M; Vishwanath S; Shen L; Ambrus JL
    Curr Pharm Biotechnol; 2014; 15(6):516-20. PubMed ID: 25091119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
    Jones A; Muller P; Dore CJ; Ikeji F; Caverly E; Chowdhury K; Isenberg DA; Gordon C; Ehrenstein MR
    BMJ Open; 2019 Dec; 9(12):e032569. PubMed ID: 31848169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Connective tissue diseases: The conundrum of B cell depletion in SLE.
    Sanz I
    Nat Rev Rheumatol; 2009 Jun; 5(6):304-5. PubMed ID: 19491910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epratuzumab for the treatment of systemic lupus erythematosus.
    Geh D; Gordon C
    Expert Rev Clin Immunol; 2018 Apr; 14(4):245-258. PubMed ID: 29542345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.